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There is no consensus on the appropriate cut-off level for the ratio between forced expiratory
volume and vital capacity (FEV1/VC) for the diagnosis of chronic obstructive pulmonary disease
(COPD). Application of a fixed ratio of 0.7 carries the risk of false positive diagnoses in elderly
subjects and false negative diagnoses in younger subjects. The use of the lower limit of normal
(LLN) of an individually predicted value should eliminate this problem. There is insufficient in-
formation about the outcome of elderly subjects with an FEV1/VC < 0.7 but above the LLN.
We report lung function (spirometry and lung clearance index, LCI), mortality and risk of
cardiac events in relation to FEV1/VC in a population-based sample of men examined at age
55 years. We stratified subjects as having FEV1/VC  0.7 (N), <0.7 but > LLN (FRþ) and
<0.7 and <LLN (FRþLLNþ). Hazard ratio for death was 1, 1.33 (0.94e1.9) and 1.71 (1.3
e2.2), respectively, when adjusted for smoking and a number of cardiovascular risk factors.
In contrast, there was no increase in the corrected hazard ratio for cardiac events. FEV1 pro-
gressively declined and LCI increased from N to FRþ and FRþLLNþ.
Subjects with FEV1/VC ratio below 0.7 but above the lower limit of normal form an interme-
diate group with respect to lung function impairment and mortality rates. Careful evaluation
of patient history and extended lung function testing may be warranted in subjects with FEV1/
VC < 0.7 but above the lower limit of normal.
ª 2013 Elsevier Ltd. All rights reserved.0331441.
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Although spirometry has a pivotal role in the diagnosis of
chronic obstructive pulmonary disease (COPD), there is no
agreement on the diagnostic criteria. Guidelines focus on
the ratio between forced expiratory volume in 1 s and the
forced vital capacity (FEV1/FVC ratio), where the Global
Initiative for Obstructive Lung Disease (GOLD) [1] advocate
a fixed ratio of 0.7 as a cut-off value. The guidelines issued
by the American Thoracic Society and the European Res-
piratory Society [2] instead favour use of the lower limit of
normal (fifth percentile; LLN) of the individually predicted
value. As FEV1/FVC is well known to decrease with age in
healthy subjects, there is a risk of over-diagnosis of COPD in
elderly subjects and under-diagnosis in young subjects, see
Mohamed Hoesein et al. [3] for references. These issues
have incited considerable controversy Table 1.
Ultimately, the choice of cut-off values should be based
on outcome, but few such studies are available. Mannino
et al. [4] studied a population aged 65 years and found
subjects with an FEV1/FVC <0.7 but above the LLN to have
increased risk of mortality (hazard ratio 1.3) and of COPD-
related hospitalisation (hazard ratio 2.6) during follow-up
compared with asymptomatic individuals with normal lung
function. Vaz Fragoso et al. [5], in subjects aged 65e80
years, found increased risk of death only in subjects with an
FEV1/FVC below the LLN. They did not, however, specif-
ically study the group of subjects with an FEV1/FVC be-
tween 0.7 and the LLN. Akkermans et al. [6], recently
published information about FEV1 decline in the Lung
Health Study (LHS). They found that subjects with an FEV1/Table 1 Subjects details, results of measurements and follow-u
FEV1/VC 
Group N
N 545
Height, m 1.75  0.
BMI, kg/m2y 24.6  3.
Current smoker, %y 58
Ever-smoker, % 83
Diabetes, % 2.0
Plasma cholesterol, mmol/L 6.39  1.
Heart rate, min1 66.8  12
Systolic blood pressure 139  22
Diastolic blood pressure 85  12
Blood pressure treatment n (%) 33 (6.1)
VC, Ly 4.4  0.7
FEV1, L
y 3.5  0.6
Lung clearance indexy 7.9  1.6
Cardiac eventsa, n (/1000) 142 (14)
Cardiac events, adjusted hazard ratioa,b (95% CI) 1.00
Deaths, n (/1000) 310 (27)
Deaths, adjusted hazard ratioyb (95% CI) 1.00
Data are presented as mean  SD unless otherwise indicated. LLN: low
forced expiratory volume in 1 s.
y: p < 0.05.
a Men with a history of myocardial infarction or angina pectoris exc
b Adjusted for current smoking, former smoking, BMI, diabetes, syst
treatment for hypertension.FVC <0.7 but above the LLN had similar rate of decline as
subjects with an FEV1/FVC >0.7. The LHS, however, was an
interventional study including only active smokers with
FEV1/FVC <0.7 [7]. The analysis includes no adjustment for
baseline FEV1 or for treatment. The interpretation of this
study is therefore not straightforward. We report survival in
relation to the FEV1/VC ratio in a population-based sample
of men followed up during 28 years.
Material and methods
The cohort “Men born in 1914” includes all men who were
born in even-numbered months in 1914, and who lived in
Malmo¨ in 1968, thus examined at 55 years of age. Six hun-
dred and eighty-nine men took part in lung function tests
and form the basis for this report. Details of spirometry
have been published previously [8]. Multiple-breath nitro-
gen washout was also performed and lung clearance index
calculated (LCI) [9]. Details of questionnaires and other
examinations have been published by Engstro¨m et al. [8]
and the method of follow-up of deaths and cardiac events
(i.e. fatal or non-fatal myocardial infarction or death due
to ischemic heart disease) by Engstro¨m et al. [10]. One-way
analysis of variance and Pearson’s chi-square was used to
compare baseline characteristic between men with FEV1/
VC  0.70, men meeting both criteria and men meeting the
fixed ratio criterion only. European reference values were
used for calculation of LLN [11]. Cox’s proportional hazards
regression was used to compare incidence of death and
cardiac events, with adjustments for potential confounding
factors.p.
0.7 FEV1/VC < 0.7, LLN FEV1/VC < 0.7, <LLN
FRþ FRþLLNþ
56 88
06 1.75  0.07 1.76  0.07
0 24.6  3.3 23.7  3.2
75 75
87 92
1.8 3.4
14 6.48  1.03 6.21  1.10
.0 63.3  12.5 65.3  10.9
141  23 139  21
84  14 84  12
1 (1.8) 7 (8.0)
4.2  0.7 4.2  0.8
2.9  0.4 2.5  0.6
8.5  1.2 8.9  1.7
20 (21) 17 (13)
1.38 (0.86e2.2) 0.97 (0.58e1.6)
39 (36) 70 (46)
1.33 (0.94e1.9) 1.71 (1.3e2.2)
er limit of normal; BMI: body mass index; VC: vital capacity; FEV1:
luded from analysis of cardiac events.
olic blood pressure, cholesterol, physical activity (three groups),
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Subject characteristics and results are presented in the
Table. Subjects with FEV1/VC < LLN (FRþLLNþ) had slightly
lower body mass index than the other groups. The propor-
tion of smokers was, as expected, higher in the groups with
lower lung function. FEV1 was considerably lower in the
subjects meeting both criteria for COPD (FRþLLNþ) than in
the subjects with FEV1/VC  0.7. The intermediary group
(FRþ) also had intermediary FEV1. Similar differences be-
tween groups were seen for LCI, indicating progressively
increasing inhomogeneity of ventilation in subjects in the
FRþ and FRþLLNþ groups. Hazards ratio for death was 1.33
(0.94e1.9) in FRþ group and 1.71 (1.3e2.2) in FRþLLNþ
group, adjusted for smoking and a number of cardiovascular
risk factors. In contrast, there was no increase in the cor-
rected hazard ratio for cardiac events.
Discussion
This study indicates that subjects with FEV1/VC < 0.7 but
above LLN have impaired lung function relative to subjects
with FEV1/VC  0.7 when extended lung function tests are
performed. Similarly to the present results, we have, in
another cohort, found that lung function is impaired in
subjects meeting the fixed ratio but not the LLN criteria,
compared to subjects with FEV1/VC  0.7 (Wollmer et al.,
submitted for publication). Gu¨der et al. [12] compared the
spirometric criteria for COPD to an expert opinion based on
all available diagnostic information. They found that the
fixed ratio over-diagnosed and LLN under-diagnosed COPD
relative to the expert diagnosis. Adding other information
about lung function brought the definitions closer to the
expert diagnosis. Taken together, these three studies indi-
cate that patients with FEV1/VC < 0.7 but above LLN
frequently have airways disease.
FEV1 and FEV1/VC arewell known to be predictors of death
not only from COPD but also from cardiovascular disease, lung
cancer and all causes [4,5,13]. Since cardiovascular events
were not significantly increased in the FRþ group andwewere
able to correct for many risk factors for atherosclerosis, the
increased mortality in the FRþ group is unlikely to be
explained by cardiovascular disease. Since we find reduced
FEV1 as well as increased LCI in the FRþ group, the increased
mortality may well be caused by respiratory disease.
In summary, this analysis of a population-based sample of
middle-aged men shows that subjects with FEV1/VC ratio
below 0.7 but above the lower limit of normal form an in-
termediate group with respect to lung function impairment
andmortality rates. Careful evaluation of patient history and
extended lung function testingmay bewarranted in subjects
with FEV1/VC < 0.7 but above the lower limit of normal.
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